Clinical Trial Update: A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating OPB-111001 in multiple advanced cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endometrial Cancer
• Ovarian Cancer
• Prostate Cancer
• Salivary Gland Cancer
• Squamous Cell Carcinoma of the Cervix

Drugs mentioned

• OPB-111001

Snippet

Sponsor: Otsuka Novel Products GmbH | Conditions: Prostate Cancer, Salivary Gland Cancer | Phase 1, Phase 2 | Status: TERMINATED